Preeclampsia triggers cellular senescence—a state where cells stop dividing but release inflammatory molecules—creating a mechanistic bridge between this pregnancy disorder and long-term cardiovascular disease. The condition affects 5% of pregnancies globally and leaves women with significantly elevated risks of hypertension, heart disease, and kidney dysfunction that persist for decades. This senescence paradigm represents a conceptual breakthrough in understanding why a temporary pregnancy complication creates permanent health vulnerabilities. Unlike traditional views that focused on acute vascular damage, this framework suggests preeclampsia seeds the body with senescent cells that continue secreting inflammatory factors long after delivery. The implications are profound: women with preeclampsia histories may benefit from senolytic drugs that selectively eliminate these problematic cells, or senomorphic therapies that suppress their inflammatory output. This connects preeclampsia research to the rapidly advancing field of aging biology, where senolytics show promise for extending healthspan. However, the evidence remains largely observational, and translating senescence-targeting therapies from laboratory to clinical practice will require extensive safety studies in reproductive-age women. This represents an emerging but potentially transformative approach to preventing long-term complications in millions of women worldwide.